Targeted Medical Pharma Releases Promising Trial Results for the Treatment of Posttraumatic Stress Disorder

Study Shows Medical Foods Sentra AM and Sentra PM Effective at Reducing Symptoms of PTSD in Veterans

Los Angeles, CA, October  13, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM) a drug discovery and development company, today announced the results of a clinical trial studying the amino acid based medical foods, Sentra AM and Sentra PM in Veterans suffering from symptoms associated with Posttraumatic Stress Disorder (PTSD).

In this 30 day open label pilot study (n=21), published in the Journal of Central Nervous System Disease, eligible subjects taking the medical foods Sentra AM and Sentra PM for thirty days showed a significant reduction in PTSD symptoms such as fatigue, cognitive dysfunction, sleep disturbances, anxiety, and panic attacks as measured by the PCL-M, and an average 57 percent increase in mental health scores as measured by the SF-36. “Clinically relevant improvements in sleep quality and a reduction in daytime drowsiness were also observed in this study, outcomes that are particularly relevant for treating PTSD successfully,” said Anthony Charuvastra, M.D. clinical assistant professor of child and adolescent psychiatry at NYU Langone Medical Center, and a specialist in PTSD.

The purpose of this pilot study was to examine the benefit of  unique nutritional interventions that focus on addressing specific amino acid deficiencies in patients with PTSD, that if corrected are capable of restoring balance to the autonomic nervous system and potentially alleviating many symptoms of the disease. The current treatment options for patients with PTSD are limited, associated with a variety of harmful side effects, and do not address the unique nutritional needs of the disease.

“The positive results of this small study indicate a need for a larger double-blind study and supports the hypothesis that treating the unique amino acid and nutrient requirements of PTSD with a medical food is a vital part of any treatment program aimed at reducing the impact of PTSD,” said William Shell, M.D. CEO and CSO of Targeted Medical Pharma, Inc.

Download the full publication here or click this link: http://bit.ly/medicalfoodsforptsd

Follow us on Twitter: @tmedpharma

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a publicly traded, Los Angeles-based biotechnology company that is committed to drug discovery and development. The company currently develops and distributes amino acid based medical foods, a rapidly growing sector of medication technology, for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders using the patented system of Targeted Cellular Technology.

The company also develops a line of dietary supplements designed to support health and wellness.  TMP currently manufactures 10 proprietary amino acid based medical foods, and recently launched its first dietary supplement, Clearwayz™.  The products are sold directly to physicians and pharmacies in the U.S. The Company is also developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

# # # #